Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 474 papers, 13 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
474citing papers in PubMed, 13 pooled it
131.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
474 citing papers in PubMed, 13 syntheses or guidelines pooled it, 572 citations in OpenAlex.
- Advancements in Immunotherapy for Lung Cancer: A Meta-Analysis of Clinical Trial Outcomes.The clinical respiratory journal · 2026Pooled it
- Pooled safety profiles of bispecific antibodies targeting PD-1/CTLA-4 or PD-1/VEGF in non-small cell lung cancer: a systematic review and single-arm meta-analysis.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis.The Indian journal of medical research · 2026Pooled it
- EGFR Mutations and Recurrence Outcomes in Resected Non-Small Cell Lung Cancer: An Updated 2015-2025 Systematic Review and Meta-Analysis.Thoracic cancer · 2026Pooled it
- Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model.Health technology assessment (Winchester, England) · 2026Pooled it
- Efficacy of first-line immune checkpoint inhibitors in advanced non-small-cell lung cancer with or without brain metastases: a systematic review and network meta-analysis.Frontiers in oncology · 2026Pooled it
- A Comprehensive Evaluation of the Effectiveness and Safety of Pembrolizumab for the Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.Current cancer drug targets · 2026Pooled it
- Efficacy and safety of first-line chemoimmunotherapy versus chemotherapy alone for advanced pulmonary lymphoepithelioma-like carcinoma: a systematic review and real-world cohort study.Frontiers in immunology · 2026Pooled it
- Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016-2025).Frontiers in immunology · 2026Pooled it
- Pooled it
- Progress in immunotherapy for resectable head and neck squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2025Pooled it
- First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs.BMC cancer · 2025Pooled it
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial.Nature communications · 2026Trial
- Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.Cancer science · 2026Trial
- Longitudinal Analysis of Peripheral Blood CD4+ T-Cell Profiles and Clinical Outcomes in Metastatic Non-Small-Cell Lung Cancer Patients Following Bronchoscopic Cryotherapy and Pembrolizumab-Based Therapy.International journal of molecular sciences · 2026Trial
- Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.Cancer communications (London, England) · 2026Trial
- Efficacy of argon-helium cryoablation combined with PD-1 inhibitors in non-small cell lung cancer.Acta oncologica (Stockholm, Sweden) · 2025Trial
- Optimal timing of stereotactic radiosurgery with first-line osimertinib in EGFR-mutant non-small cell lung cancer brain metastases: Immediate, early-consolidation and salvage strategies.Oncology letters · 2026Article
414 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 17 institutions in 8 countries.
Marina C GarassinoKnapp Center for Biomedical Discovery, University of Chicago Medicine & Biological Sciences, Chicago, IL.ORCID 0000-0002-3821-5598
Shirish GadgeelHenry Ford Cancer Institute/Henry Ford Health, Detroit, MI.ORCID 0000-0001-5240-3811
Giovanna SperanzaCentre Integré de Cancérologie de la Montérégie, Hôpital Charles-Le Moyne, Greenfield Park, QC, Canada.
Enriqueta FelipMedical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0002-7620-0098
Emilio EstebanDepartment of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Manuel DómineDepartment of Oncology, Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.ORCID 0000-0002-1128-434X
Maximilian J HochmairDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Steven F PowellHematology and Oncology, Sanford Cancer Center, Sioux Falls, SD.ORCID 0000-0002-5029-0048
Helge G BischoffThoraxklinik, Heidelberg, Germany.
Nir PeledDepartment of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.ORCID 0000-0003-3714-4377
Francesco GrossiMedical Oncology Division, University of Insubria, Varese, Italy.ORCID 0000-0001-8412-3136
Ross R JennensDepartment of Medical Oncology, Epworth Healthcare, Richmond, VIC, Australia.ORCID 0000-0002-9872-997X
Martin ReckLungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.ORCID 0000-0002-5336-9739
Rina HuiDepartment of Medical Oncology, Westmead Hospital and University of Sydney, Sydney, NSW, Australia.
Edward B GaronDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0000-0001-7077-8801
Takayasu KurataDepartment of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.ORCID 0000-0003-4123-3567
Jhanelle E GrayDepartment of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL.
Paul SchwarzenbergerMerck & Co, Inc, Rahway, NJ.
Erin JensenMerck & Co, Inc, Rahway, NJ.
M Catherine PietanzaMerck & Co, Inc, Rahway, NJ.
Delvys Rodríguez-AbreuComplejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.ORCID 0000-0003-0506-1366
Merck & Co., Inc., Rahway, NJ, USA (United States) · USEpworth Hospital · AUGerman Center for Lung Research · DEHenry Ford Health System · USHôpital Charles-Le Moyne · CAHospital Universitario Central de Asturias · ESHospital Universitario Fundación Jiménez Díaz · ESKansai Medical University · JPMoffitt Cancer Center · USSanford Research · USShaare Zedek Medical Center · ILThe University of Sydney · AUUniversidad de Las Palmas de Gran Canaria · ESUniversity of California, Los Angeles · USUniversity of Chicago · USUniversity of Insubria · ITVall d'Hebron Hospital Universitari · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsHumansPemetrexedPlatinumReceptor Protein-Tyrosine KinasesAntibodies, Monoclonal, HumanizedErbB ReceptorspembrolizumabPemetrexedPlatinumReceptor Protein-Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.